Navigation Links
Matrixx Initiatives Selects GolinHarris as Agency of Record for Zicam Brand
Date:1/8/2009

Agency will lead public relations efforts to promote OTC cold and flu and allergy products

Los Angeles, CA (PRWEB) January 8, 2008 - Matrixx Initiatives, Inc., has selected GolinHarris as agency of record to lead its public relations initiatives for Zicam® LLC, a wholly owned subsidiary. The agency is charged with ongoing strategic counsel, product messaging, traditional media outreach and developing innovative social media programs. The account will be led out of the Los Angeles office by Negin Kamali, vice president, and Judy Johnson, regional managing director, with new media leadership from Scott Arenson, vice president of social media in the agency's Dialogue digital group. Zicam, one of the fastest growing over-the-counter cold products, is clinically proven to reduce the duration and severity of the common cold.
            
"We sought out an agency with a strong track record in consumer health products, traditional media relations and social media," said Bill Hemelt, Zicam's acting president. "We're especially excited about the work GolinHarris is doing for us in new media, including launching Zicam's first-ever mobile application for Google's new Android phone and the Apple iPhone, search engine optimization, as well as a number of social media applications."

"The cold and flu season is here and our work with Zicam is already in motion," said Judy Johnson, managing director of GolinHarris' western region. "The Cold and Flu Companion mobile application is just one of several strategies that we're employing to help consumers learn more about Zicam."

About Matrixx Initiatives
Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly owned subsidiary, markets and sells Zicam® and Nasal ComfortTM products in the cough and cold category. The company's flagship product, Zicam Cold Remedy nasal gel, is a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Swabs(TM); Zicam Cold Remedy ChewablesTM; Zicam Cold Remedy Oral MistTM; Zicam Cold Remedy RapidMeltsTM; Zicam Allergy Relief; Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at Matrixxinc.com. For investor information, contact Bill Barba, Treasurer, at 602-385-8881.

About GolinHarris
GolinHarris is a leading public relations agency offering a distinctive combination of global resources and personalized service in the Americas, Asia Pacific, Europe and the Middle East. Clients include Dow Chemical Company, McDonald's Corporation, Nintendo of America Inc., Orange, Texas Instruments and Toyota Motor Sales USA, Inc. GolinHarris celebrated its 50th anniversary in 2006, and is proud to have been selected as 2007 Agency of the Year by The Holmes Report, Large PR Agency of the Year in the PRWeek Awards, PRWeek Magazine's 2007 Editors' Choice and 2008 International Agency of the Year by PRCA. The agency is headquartered in Chicago and is part of the Interpublic Group of Companies (NYSE: IPG). For more information, visit GolinHarris.com or to join GolinHarris' discussion on the future of public relations, visit NextFiftyYears.com.

Media Contact: Kathy Maiorana (312) 729-4246

###

Read the full story at http://www.prweb.com/releases/ZicamGolinHarris/MatrixxAgencyofRecord/prweb1837634.htm


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
2. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
3. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
5. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
6. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
7. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
8. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. Health Plans, Employers Take Closer Look at Costs and Expand Disease Management Initiatives in Response to Diabetes Prevalence Increase
11. Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Bensonhurst, NY (PRWEB) , ... May 23, 2016 , ... ... Enrico Ferdico took the time to summarize the weight loss process: , New patients ... a Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an article published May ... massive role in oral health and hygiene. The article points out that, as long as ... their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean teeth ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... in an exuberant mood since the birth of her son, Rockwell Lloyd Liu, and ... ever had.” The “Elementary” and “Kill Bill” star explains that, as a career oriented ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical Data ... from the Japan PMDA, US FDA, industry and academia at the 2016 ... format data from clinical trials so that it can be shared and compared, ...
(Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
Breaking Medicine News(10 mins):
(Date:5/22/2016)... 23, 2016 DS Biopharma ... and anti-inflammatory compound DS102 in chronic obstructive pulmonary ... steatohepatitis (NASH) patients. Recent DS preclinical ... lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic ... The Company will publish further detail on these ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Oregon , May 19, 2016 ... titled, World Medical/Diagnostic Imaging Market -Opportunities and Forecasts, 2015 ... reach $45.0 billion by 2022, registering a CAGR of ... expected to continue to be the highest revenue-generating segment ... accounted for around one-third of the market share ...
Breaking Medicine Technology: